Agreements reached under this partnership
Capital and Business Alliance- 1
Exclusive marketing rights in Japan
- 2
Upfront contractual payment
- 3
Development milestone payments
- 4
Post-marketing royalty income
- 5
Supply of the product
- 6
After execution of the final agreement, Maruishi Pharmaceutical will make an additional investment in the company
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
This indicates whether the companies will do more than work together, such as holding each other’s shares or seconding personnel (capital and business alliance).
The execution of this basic agreement has no impact on the company's results at this time. The company will promptly disclose any matters requiring disclosure that arise in the future.
| Item | Details |
|---|---|
| Name of alliance partner | 丸石製薬株式会社 |
| Alliance partner's business activities | Manufacturing and marketing of pharmaceuticals and other products |
| Alliance partner's location | Tsurumi-ku, Osaka |
| Alliance partner's capital | ¥285 million |
| Alliance partner's net sales | ¥42.3 billion (FY2023), ¥46.0 billion (FY2024), ¥48.3 billion (FY2025) |
| Type of alliance | Capital and Business Alliance |
| Details of the alliance | Exclusive marketing rights in Japan, Upfront contractual payment, Development milestone payments, Post-marketing royalty income, Supply of the product, After execution of the final agreement, Maruishi Pharmaceutical will make an additional investment in the company |
| Shareholding ratio | 1.19% (Maruishi Pharmaceutical's ownership stake in the company) → Not disclosed |
| Date of board resolution | 15 July 2026 |
| Contract Date | 15 July 2026 (date of execution of the basic agreement) |
| Impact on Business Performance | The execution of this basic agreement has no impact on the company's results at this time. The company will promptly disclose any matters requiring disclosure that arise in the future. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To pursue a marketing partnership for the vocal fold scarring treatment drug, based on Maruishi Pharmaceutical's expertise as a specialty pharmaceutical company, extensive experience and domestic marketing structure.